Top Markets
#1 ONFA ONFA +217.91%
#2 Resolv wstUSR Resolv wstUSR +198.08%
#3 Noon Noon +41.33%
#4 Doge Strategy Doge Strategy +38.28%
#5 DeAgentAI DeAgentAI +36.64%
#6 NKN NKN +34.87%
#7 StakeStone StakeStone +29.44%
#8 BLOCKv BLOCKv +25.50%
#9 KONET KONET +24.76%
#10 OpenVPP OpenVPP +21.34%
Coin of the day
ONFA ONFA
設定
言語
日本
通貨
USD
テーマ
Ensysce Biosciences, Inc. Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc.

ENSC
株式のランク #19706
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in... Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.
株価
$0.5275
時価総額
$1.25M
変化（1日）
-3.56%
変化（1年）
-83.77%
国
US
取引 Ensysce Biosciences, Inc. (ENSC)

カテゴリー

Healthcare
Ensysce Biosciences, Inc.（ENSC）のP/E比率
March 2026 時点のP/E比率 TTM -0.11
Ensysce Biosciences, Inc. の最新の財務報告および株価によると、現在の P/E (TTM) は -0.11 です。2023 年末時点での P/E は -3.39 でした。
Ensysce Biosciences, Inc. の P/E 比率の履歴（2017 〜 2026）
各年末のP/E比率
年 P/E比率 変化
2026 (TTM) -0.11 -93.99%
2024 -1.78 -47.51%
2023 -3.39 237.53%
2022 -1.00 -97.94%
2021 -48.88 -100.00%
2020 3.52M 463.02%
2019 624.36K -494.92%
2018 -158.10K -97.60%
2017 -6.60M 0.00%
類似企業や競合他社のP/E比率
企業 P/E比率 P/E比率の差 国
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 10.72 -10,115.98%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 30.14 -28,271.96%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 17.03 -16,020.28%
US
UCB SA UCB SA
UCB SA
UCB.BR
 30.44 -28,547.20%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
 33.07 -31,009.72%
AU
P/E比率の読み方

株価収益率（P/E Ratio）は、企業の株価と1株あたり利益の関係を示します。
低いが正のP/Eは、現在の評価額に対して高い利益を上げている企業を示し、割安と見なされる可能性があります。高い負の（0に近い）P/Eは、損失が大きいことを示します。

P/Eが30を超えるか、負である企業は一般に「成長株」と見なされ、投資家は将来的な成長または黒字化を期待しています。

10未満の正のP/Eを持つ企業は一般に「割安株」と見なされ、既に収益性が高いが成長の余地は小さいと見なされます。